ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

OCUL vs GPCR // RETURN ON INVESTED CAPITAL (ROIC)

Ocular Therapeutix Inc. (NASDAQ) VS. Structure Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: OCUL 4 — GPCR 1
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: GPCR
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (OCUL VS. GPCR) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC OCUL GPCR SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 87.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -19.50% -15.50 GPCR /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield -13.51% -14.43% +0.92 OCUL /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -18.50% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 4.31 — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 1/9 +2.00 OCUL /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 47.5 27.1 +20.40 OCUL /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $1.61B $1.56B $40.9M OCUL /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR OCUL REV GPCR REV OCUL GROSS % GPCR GROSS % OCUL FCF GPCR FCF
FY 2025 $52.0M $0 87.3% — -$216.9M -$225.8M
FY 2024 $63.7M $0 91.2% — -$136.0M -$117.9M
FY 2023 $58.4M $0 — — -$70.2M -$79.5M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
OCUL // BETA —
GPCR // BETA —